MONOCLONAL ANTIBODIES THAT BIND SPECIFICALLY TO HUMAN TRBV9

The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a metho...

Full description

Saved in:
Bibliographic Details
Main Authors STAROVEROV, Dmitry Borisovich, IAKOVLEV, Pavel Andreevich, NEMANKIN, Timofey Aleksandrovich, MOROZOV, Dmitry Valentinovich, BRITANOVA, Olga Vladimirovna, MISORIN, Alexey Konstantinovich, VLADIMIROVA, Anna Konstantinovna, EVSTRATEVA, Anna Valentinovna, IVANOV, Roman Alekseevich, LUKYANOV, Sergey Anatolievich, SHELEVA, Mariia Aleksandrovna, ANIKINA, Arina Vitalevna
Format Patent
LanguageEnglish
Published 24.02.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.
Bibliography:Application Number: US201917417570